Plasminogen activator inhibitor-1: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
'''Plasminogen | == Plasminogen Activator Inhibitor-1 (PAI-1) == | ||
[[File:Fibrinolysis.svg|thumb|right|Diagram of the fibrinolysis process, showing the role of PAI-1.]] | |||
'''Plasminogen Activator Inhibitor-1''' ('''PAI-1''') is a protein that plays a crucial role in the regulation of the [[fibrinolysis]] system. It is a member of the [[serpin]] (serine protease inhibitor) superfamily and is the principal inhibitor of the [[plasminogen activator]]s, [[tissue plasminogen activator]] (tPA) and [[urokinase plasminogen activator]] (uPA). PAI-1 is encoded by the [[SERPINE1]] gene in humans. | |||
== Function == | == Function == | ||
PAI-1 is primarily involved in the inhibition of fibrinolysis, the process that prevents blood clots from growing and becoming problematic. By inhibiting tPA and uPA, PAI-1 controls the conversion of [[plasminogen]] to [[plasmin]], the enzyme responsible for breaking down [[fibrin]] clots. This regulation is essential for maintaining the balance between clot formation and dissolution, which is critical for normal [[hemostasis]]. | |||
== Regulation == | |||
The activity of PAI-1 is regulated at multiple levels, including transcriptional, post-transcriptional, and post-translational modifications. Factors such as [[cytokines]], [[hormones]], and [[growth factors]] can influence PAI-1 expression. Additionally, PAI-1 activity is modulated by its interaction with other proteins, such as [[vitronectin]], which stabilizes PAI-1 in its active form. | |||
== Clinical Significance == | |||
[[File:Fibrinolysis.svg|thumb|left|PAI-1's role in inhibiting fibrinolysis.]] | |||
Elevated levels of PAI-1 are associated with an increased risk of [[thrombosis]], as excessive inhibition of fibrinolysis can lead to the persistence of blood clots. This condition is linked to various [[cardiovascular diseases]], including [[myocardial infarction]] and [[stroke]]. Conversely, PAI-1 deficiency can lead to a bleeding tendency due to excessive fibrinolysis. | |||
PAI-1 is also implicated in [[metabolic syndrome]], [[obesity]], and [[insulin resistance]]. It is considered a marker of [[inflammation]] and is involved in the pathophysiology of [[fibrosis]] and [[cancer]] metastasis. | |||
== | == Related Pages == | ||
* [[Fibrinolysis]] | * [[Fibrinolysis]] | ||
* [[ | * [[Plasminogen]] | ||
* [[Tissue plasminogen activator]] | |||
* [[Urokinase plasminogen activator]] | |||
* [[Serpin]] | * [[Serpin]] | ||
{{Fibrinolysis}} | |||
[[Category:Proteins]] | [[Category:Proteins]] | ||
[[Category: | [[Category:Hematology]] | ||
[[Category: | [[Category:Serine protease inhibitors]] | ||
Latest revision as of 16:28, 16 February 2025
Plasminogen Activator Inhibitor-1 (PAI-1)[edit]
Plasminogen Activator Inhibitor-1 (PAI-1) is a protein that plays a crucial role in the regulation of the fibrinolysis system. It is a member of the serpin (serine protease inhibitor) superfamily and is the principal inhibitor of the plasminogen activators, tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA). PAI-1 is encoded by the SERPINE1 gene in humans.
Function[edit]
PAI-1 is primarily involved in the inhibition of fibrinolysis, the process that prevents blood clots from growing and becoming problematic. By inhibiting tPA and uPA, PAI-1 controls the conversion of plasminogen to plasmin, the enzyme responsible for breaking down fibrin clots. This regulation is essential for maintaining the balance between clot formation and dissolution, which is critical for normal hemostasis.
Regulation[edit]
The activity of PAI-1 is regulated at multiple levels, including transcriptional, post-transcriptional, and post-translational modifications. Factors such as cytokines, hormones, and growth factors can influence PAI-1 expression. Additionally, PAI-1 activity is modulated by its interaction with other proteins, such as vitronectin, which stabilizes PAI-1 in its active form.
Clinical Significance[edit]
Elevated levels of PAI-1 are associated with an increased risk of thrombosis, as excessive inhibition of fibrinolysis can lead to the persistence of blood clots. This condition is linked to various cardiovascular diseases, including myocardial infarction and stroke. Conversely, PAI-1 deficiency can lead to a bleeding tendency due to excessive fibrinolysis.
PAI-1 is also implicated in metabolic syndrome, obesity, and insulin resistance. It is considered a marker of inflammation and is involved in the pathophysiology of fibrosis and cancer metastasis.
